Immuron

Immuron Ltd. engages in the research and development of oral immunotherapy, which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment is involved in research and development projects performed in Australia, Israel, and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.

Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. Its proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. This technology can be used to target viruses or bacteria and neutralize the toxins they produce on mucosal surfaces. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment includes projects performed in Australia and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994, and is headquartered in Carlton, Australia.

US DoD Naval Medical Research Center Receives FDA Guidance on the clinical development plans for new oral therapeutic

Immuron Partners with CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of Defense

The day traders are back at it, chasing stocks on news with very few thoughts about what the fundamentals may be if the good news pans out.

Can the 800% Gain in Immuron Be Rationalized Very Easily?

The U.S.-listed shares of of Immuron Ltd. IMRN, 1,152.32% skyrocketed nearly 10-fold on massive volume in afternoon trading Tuesday

Immuron's stock blasts off nearly 10-fold after partner NMRC seeks pre-IND meeting with FDA

Shares of Australian biopharma IMMURON LTD/S ADR (NASDAQ: IMRN) are on a roll Tuesday on the back of financing deal for one of its pipeline assets.

Immuron's Stock Surges 300% On US Navy Contract

US DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute Infectious Diarrhea

MELBOURNE, Australia, April  28, 2020  (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced that the cash payments of Board fees will be suspended and replaced with Immuron stock.

Immuron Board Relinquish Cash Payment of Fees

Immuron North American Travelan® Sales Up 95%, Global Sales Up 60%

MELBOURNE, Australia, March  25, 2020  (GLOBE NEWSWIRE) -- The Directors and Management of Immuron wish to provide an update to the market regarding the current and future impact of COVID-19 on the Company.

Resignation of CEO & Director and cost cutting amidst COVID-19

Immuron Provides Update on First Half of FY20 Results

Immuron’s Technology Platform of Treatments in the Age of the Coronavirus Outbreak

North American Travelan® sales up 98% in the first half of FY20

Immuron Plans Phase 3 trial for IMM-124E to Prevent Travelers’ Diarrhea

MELBOURNE, Australia, Nov.  04, 2019  (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of AUD $0.53 million for eligible research and development expenditure incurred during the 2019 Financial Year.

Immuron Receives AUD $0.53M R&D Tax Concession Refund

Immuron North American Q1 Sales Up 111% YoY

Shares of thinly traded nano-cap biotech IMMURON LTD/S ADR (NASDAQ: IMRN) were off to a flying start Wednesday morning.

Immuron Receives $3.7M In Federal Dollars For Traveler's Diarrhea Preventative Therapy Project

New U.S. Department of Defense Research Collaboration with Immuron to Develop and Clinically evaluate a New Therapeutic against Campylobacter

U.S. Defense Reports Immuron’s Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of travelers’ diarrhea

Shares of Australian nano-cap biotech Immuron (NASDAQ: IMRN) rose sharply Wednesday on roughly 250 times average volume.

News for Immuron Stock (IMRN)